BioCentury
ARTICLE | Clinical News

Ranexa ranolazine: Phase III started

October 18, 2004 7:00 AM UTC

CVTX began the double-blind, placebo-controlled, international Phase III MERLIN TIMI-36 trial in about 5,500 patients with non-ST elevation acute coronary syndromes (ACS). The company said this trial,...